Industry news

Japan readies to sign new IP law it sees as win-win

EJ Lane / FeircePharmaAsia

Japan is due to sign off on an international intellectual property patent treaty that would require it to make some reforms in its own laws to make it easier for foreigners to apply. But its own exporting companies also stand to benefit.

The 25 most influential people in biopharma in 2015

John Carroll / FierceBiotech

A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to get other prominent people in this business to rethink the way they do business. 

FDA Revises Field Inspections to Reflect Global Market and Quality Initiatives

Jill Wechsler / BioPharm International.com

The globalization of drug production has prompted FDA to overhaul its strategies for ensuring the safety and quality of drugs and biologics coming into the United States, as well as those produced at home. Recent legislation enhancing FDA inspection authority supports stiffer enforcement of manufacturing standards, along with added incentives for establishing high quality operations. 

Next opportunity: Will China's e-commerce revolution lead to accessible biologics?

Shannon Ellis / BioWorld

Each year investors looking to ride the next big wave of opportunity convene at China's Healthcare Investment Conference to test the waters. This year, the promise of technology to tackle some of China's most complicated health care woes, summed up by the term e-Health, generated the most buzz.

As IPO market wanes, biotechs turn to reverse mergers

Brian Orelli / BioWorld

Through the first four months of the year, BioWorld Snapshots tracked 24 IPOs by drug companies on U.S. and international exchanges compared to 36 in the same time period last year.

14 May 2015

Neothetics Reports First Quarter 2015 Financial Results

Neothetics, Inc.  (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today reported financial results for the first quarter 2015.

Push to use big data in Japan gets help from industry, academia

EJ Lane / FeircePharmaAsia

The pharmaceutical industry's producers and academic researchers in Japan are actively engaged, despite setbacks experienced by others such as Google ($GOOG), in building a big-data pipeline, this one now including 10 drugmakers and 30 medical institutions.

Supercooled nanoparticles offer targeted delivery approach

Michael Gibney / FierceDrugDelivary

The ability to supercool drug-carrying vesicles inside the body and time the exact moment of crystallization could lead to a targeted approach to drug delivery, researchers at Tel Aviv University have found.

China gears up to change the rules of the game on drug sales

EJ Lane / Feirce Biotech

If China has its way, within another year or two, a repeat of the GlaxoSmithKline ($GSK) and similar scandals will be far less likely, but drugmakers can expect to face a harder sell as a result. The government just completed a comprehensive healthcare reform plan centered on the nation's public hospital system, but with a reach throughout the medical process.

Google signs on Harvard doc to lead bioinformatics study

Emily Wasserman / FierceMedicalDevices

Google's Baseline study is getting a boost, with a Harvard cardiologist moving over to lead the initiative almost a year after the company revealed its plans to aggregate molecular and genetic data to jump-start medical research.